FRANKFURT, Sept 24 (Reuters) - AstraZeneca is still
waiting for the go-ahead from the U.S. drug regulator to restart
the clinical trial of its COVID-19 vaccine hopeful in the United
States, Chief Executive Pascal Soriot said on Thursday.
"We are awaiting to hear their decision," Soriot told a
virtual World Economic Forum discussion.
(Reporting by Ludwig Burger
Editing by Caroline Copley)